Altor BioScience Awarded SBIR Phase I Grant by NCI for Research on its Novel IL-15 Super Agonist for Bladder Cancer
Miramar, Florida, August 17, 2011 - - Altor BioScience Corporation (Altor) announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant by the National Cancer Institute.
The award of $225,279 for the project entitled “Novel IL-15 Superagonist Therapy for Bladder Cancer” will provide Altor the necessary resources to complete the ongoing evaluation of its interleukin-15 (IL-15) superagonist complex, designated ALT-803, against superficial bladder cancer in relevant pre-clinical models. Confirmation of earlier positive outcomes from these studies would provide justification for developing ALT-803 as a safe, durable, potentially curative treatment for patients with superficial bladder cancer. Superficial bladder cancer, with 50,000 newly diagnosed cases in the United Sates annually, is the most expensive cancer to treat on a “per patient” basis due to its high frequency of recurrence. The current best treatment option is to use Bacillus Calmette-Guerin (BCG) therapy, which is inadequate in a majority of cases.
Hing Wong, Ph.D., Altor's CEO commented, "Altor is extremely pleased to receive this SBIR award from NCI and the recognition that Altor’s novel and proprietary IL-15 based immunotherapeutic could address an important unmet medical need. Altor’s top clinical priority is to move ALT-803 into clinical development in the first quarter of 2012.” As announced on June 28, 2011, Altor and Florida Biologix have linked up for the manufacture of ALT-803 cGMP material for clinical development.
In addition to this SBIR grant award, Altor’s collaborator, Dr. C. J. Rosser of the MD Anderson Cancer Center in Orlando, was awarded a James & Esther King Biomedical Research Grant of $1.3 million, funded by the State of Florida Department of Health, to support pre-clinical and clinical development of ALT-803 for superficial bladder cancer.
About Altor’s IL-15 Technology
IL-15 is related to the approved immunotherapeutic, IL-2, and is a critical factor for the development, proliferation and activation of cellular immune responses. Altor has developed ALT-803, a novel IL-15 superagonist complex with enhanced biological activity in vitro and in vivo. ALT-803 is currently in pre-clinical testing as a potential treatment for patients with superficial bladder cancer, other solid and hematological tumors.
About Altor BioScience
Altor is a privately held biotechnology company developing immunotherapies for treating cancer, viral infections, and inflammatory diseases based on its proprietary technology platforms. Altor currently has two products in clinical development. ALT-801 is Altor’s lead product based on its T -cell receptor (TCR) technology. This TCR-targeted immunotherapeutic for cancer currently in Phase II trials to evaluate its safety and clinical utilies for treatment of patients with metastatic melanoma and for treatment of patients with advanced or metastatic urothelial cancer.
A monoclonal antibody-based Tissue Factor antagonist, referred to as ALT-836, is in a second multi-center Phase II trial for treatment of patients with Acute Respiratory Distress Syndrome and Acute Lung Injury, a life-threatening, systemic inflammatory disease. ALT-836, in combination with gemcitabine, is also in a Phase I/IIa clinical trial for treating patients with solid tumors.
Visit www.altorbioscience.com for details.
Contact: Altor Bioscience Corporation, Peter Rhode, Ph.D., 954-443-8600